Literature DB >> 30712756

Cutaneous Leishmaniasis: Updates in Diagnosis and Management.

Naomi E Aronson1, Christie A Joya2.   

Abstract

Cutaneous leishmaniasis (CL) is a diverse human disease caused by more than 20 Leishmania species transmitted by the bite of an infected sand fly. Diagnostic testing is recommended to confirm infection and determine the infecting species. Treatment decisions are complex and providers should consider infecting species, patient comorbidities, extent and location of lesions, and previous treatments. There is no single universal treatment for CL and some treatment can have toxicity. Treatment should be individualized and factors, such as self-healing nature of this infection, risk of metastatic complications (ie, mucosal leishmaniasis), and patient wishes, need to be included in individual risk-benefit treatment decisions. Published by Elsevier Inc.

Entities:  

Keywords:  Amphotericin; Antimony; Cutaneous leishmaniasis; Leishmaniasis diagnostic testing; Miltefosine

Mesh:

Substances:

Year:  2019        PMID: 30712756     DOI: 10.1016/j.idc.2018.10.004

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  12 in total

1.  In vitro activity of Erythrophleum ivorense extract against the promastigote stage of cutaneous Leishmania parasite, a member of Leishmania (Mundinia) enriettii complex isolates from Ghana.

Authors:  Alberta Serwah Anning; Godwin Kwakye-Nuako; Elvis Ofori Ameyaw; Mba-Tihssommah Mosore; Kwame Kumi Asare
Journal:  Access Microbiol       Date:  2019-09-03

2.  Case Report: Cutaneous Leishmaniasis due to Leishmania (Viannia) panamensis in Two Travelers Successfully Treated with Miltefosine.

Authors:  S Mann; T Phupitakphol; B Davis; S Newman; J A Suarez; A Henao-Martínez; C Franco-Paredes
Journal:  Am J Trop Med Hyg       Date:  2020-09       Impact factor: 2.345

Review 3.  A Review of Leishmaniasis: Current Knowledge and Future Directions.

Authors:  Sarah Mann; Katherine Frasca; Sara Scherrer; Andrés F Henao-Martínez; Sabrina Newman; Poornima Ramanan; José A Suarez
Journal:  Curr Trop Med Rep       Date:  2021-03-17

4.  A machine learning-based system for detecting leishmaniasis in microscopic images.

Authors:  Mojtaba Zare; Hossein Akbarialiabad; Hossein Parsaei; Qasem Asgari; Ali Alinejad; Mohammad Saleh Bahreini; Seyed Hossein Hosseini; Mohsen Ghofrani-Jahromi; Reza Shahriarirad; Yalda Amirmoezzi; Sepehr Shahriarirad; Ali Zeighami; Gholamreza Abdollahifard
Journal:  BMC Infect Dis       Date:  2022-01-12       Impact factor: 3.090

5.  Methodological Appraisal of Literature Concerning the Analysis of Genetic Variants or Protein Levels of Complement Components on Susceptibility to Infection by Trypanosomatids: A Systematic Review.

Authors:  Thais Cristina Tirado; Larine Lowry Moura; Patrícia Shigunov; Fabiano Borges Figueiredo
Journal:  Front Immunol       Date:  2021-11-25       Impact factor: 7.561

6.  Multiple ulcerated lesions in a patient from Amazon, Brazil.

Authors:  Nathalia Miranda Souto; Sidharta Quercia Gadelha; Virginia Vilasboas Figueiras; Rosilene Viana de Andrade; Luciana Mendes Dos Santos
Journal:  JAAD Case Rep       Date:  2022-02-05

7.  Past and future of trypanosomatids high-throughput phenotypic screening.

Authors:  Rafael Ferreira Dantas; Eduardo Caio Torres-Santos; Floriano Paes Silva
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-03-11       Impact factor: 2.743

8.  Cutaneous leishmaniasis in a 12-year-old Syrian immigrant.

Authors:  Mohammad Alghounaim; Jeffrey Chivinski; Sapha Barkati
Journal:  CMAJ       Date:  2022-01-24       Impact factor: 8.262

9. 

Authors:  Mohammad Alghounaim; Jeffrey Chivinski; Sapha Barkati
Journal:  CMAJ       Date:  2022-03-28       Impact factor: 8.262

10.  A Novel Anti-Microbial Peptide from Pseudomonas, REDLK Induced Growth Inhibition of Leishmania tarentolae Promastigote In Vitro.

Authors:  Yanhui Yu; Panpan Zhao; Lili Cao; Pengtao Gong; Shuxian Yuan; Xinhua Yao; Yanbing Guo; Hang Dong; Weina Jiang
Journal:  Korean J Parasitol       Date:  2020-04-30       Impact factor: 1.341

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.